290 Munro St, Thunder Bay, ON P7A 7T1
Toll-free: 1-877-868-5044
Mitomic Testing.
A revolution in disease detectionand prognosis
Using our Mitomic Technology, Mitomics Inc. has developed an advanced portfolio of solutions for disease detection and prognosis. We currently have, or are developing, Mitomic Tests for the early detection of Prostate, Ovarian and Lung Cancers and Endometriosis.
Mitomic Prostate Test
For the measurement of the 3.4 kb deletion to determine risk of significant prostate cancer
The Mitomic Prostate Test is the most accurate way of determining if a patient is at risk of having clinically significant prostate cancer, outperforming every other test on the market with just a simple blood test. Its high negative predictive value for clinically significant cancer enables more accurate and informed biopsy decisions.
-
A simple blood test with unrivalled accuracy
-
97-100% negative predictive value
-
Independent of PSA and age
-
No algorithm, just a simple yes or no
Mitomic Endometriosis Test
176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose
MET is the first ever non-invasive blood-based test. It identifies the 8.7kb mitochondrial DNA deletion, a new and accurate biomarker of endometriosis with the potential to significantly reduce the diagnostic delay and stall disease progression with earlier intervention.